What is Dyne Therapeutics Inc?
, a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.90B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 922,117 shares $422k | 12,500 shares $40k |
| 3-6months | 102,595,493 shares $65.4M | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |